In many respects, we don't expect them to be included in formularies in the same way common drugs are. The formulary implies that almost anybody can prescribe it, unless the drugs are quite restricted. We believe there needs to be, for most of these drugs, managed-access programs. We believe they need to come in with, as Professor Herder was talking about, clear criteria for who gets access. We need to have start-stop criteria and know if the patients fit the criteria. What's happening is that in many cases these start-stop criteria in Canada are very impoverished relative to those in the rest of the world.
The other thing that's so important is that we need to be part of international monitoring. In this regard, I just came back from the European Congress on rare diseases, and I just came back from ISPOR in Washington and HTAi. There is not enough of such monitoring in Canada with these rare-disease drugs. We need to be much more in sync with what is happening in Europe—and I mean Europe even more than the U.S. This is the problem with our not having an orphan drug regulatory formulary. Our drugs don't come in at the same time. They come in with different conditions sometimes. We start to collect evidence, but we only have a small amount of evidence. We bring in the drugs on the basis of the evidence that Health Canada and the international community can approve in terms of safety and efficacy. We then continue to collect evidence and we continue to reassess. We reassess on an individual basis—